← Leaderboards
William D Henner
Oregon Health And Science University
$513,326
Attributed
$513,326
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$513,326 · 3
By mechanism
M01$344,822 · 2
P30$168,504 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Edward A Neuwelt$27,752,214
- Grover Carlton Bagby$13,295,923
- Tomasz M Beer$2,631,430
- Mathew J Thayer$9,087,500
- Thomas Mark Becker$29,313,453
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectCancer RiskDrug Screening /EvaluationFamily GeneticsGenetic PolymorphismGenetic ScreeningHealth BehaviorVolunteerBloodProstate NeoplasmsProstate Specific AntigenRacial /Ethnic DifferenceVitamin Therapy1,25 DihydroxycholecalciferolHuman Genetic Material TagHuman Therapy EvaluationMass ScreeningNeoplasm /Cancer ChemotherapyNeoplasm /Cancer DiagnosisNeoplasm /Cancer GeneticsNutrition Related TagHistopathologySample Collection
Grant awards (7)
DNA POLYMORPHISMS &CANCER RISKS$172,411
M01 · FY2001 · RR
Pulse calcitriol in patients with rising PSA after treatement for prostate cancer$172,411
M01 · FY2001 · RR
DNA POLYMORPHISMS &CANCER RISKS$0
M01 · FY2001 · RR
Pulse calcitriol in patients with rising PSA after treatement for prostate cancer$0
M01 · FY2001 · RR
CORE--TUMOR PROCUREMENT$168,504
P30 · FY2000 · CA
Pulse calcitriol in patients with rising PSA after treatement for prostate cancer$0
M01 · FY2000 · RR
DNA POLYMORPHISMS &CANCER RISKS$0
M01 · FY2000 · RR